Similar to other repurposed compounds previously evaluated for AxD, such as curcumin and ceftriaxone (Bachetti et al., 2010b; Bachetti et al., 2012), the molecules taken into consideration in the present work have displayed a variable range of beneficial effects, including the induction of HSP27 and alphaB-crystallin cellular expression, reduction of cellular GFAP levels by interfering with its gene expression, and elimination of the p. R239C mutant protein (Figure 8). Here, GFAP is linked to Alexander disease.